St. Petersburg, Florida – October 16, 2026 -- Attilio, a longevity platform launched in September 2026, has appointed Dr. Eric Verdin, President and CEO of the Buck Institute for Research on Aging, as Co-Chairman. The company prices the Dr. Verdin Baseline Assessment(TM), built on his research, at $2,500 per member.

Los Angeles – October 16, 2026 -- TORL BioTherapeutics has appointed Sandip Kapadia as Chief Financial Officer, a executive who has raised more than $2 billion in public capital for emerging biotechnology companies, and Eric Sievers, M.D., as Chief Medical Officer, completing a year-long expansion of its leadership team.

Berlin – October 16, 2026 -- Aignostics has launched HETA Clinical, a family of pan-cancer AI products aimed at the 10% to 20% of molecular tests that pathologists estimate fail because tissue contains too little tumor.

The first four products analyze whole slide H&E images across the pathology workflow, from intake and evaluation through to molecular testing. The company says the suite helps labs prioritize cases, cut turnaround time and confirm sufficient tumor content before molecular testing begins.

Boston – October 16, 2026 -- Perceptive Discovery has become the first US provider able to run astatine-211 (At-211) radiopharmaceutical development studies, now available at its US and UK sites through a collaboration with Atley Solutions.

First Atley C100 module purifies At-211 at QMUL laboratory in London

At Perceptive Discovery's laboratory at Queen Mary University of London (QMUL), the first Atley C100 module in the collaboration is installed. It has been used to purify At-211 from an irradiated bismuth-209 target.

SAN DIEGO – October 15, 2026 -- QuidelOrtho Corporation (Nasdaq: QDEL) has granted restricted stock units covering an aggregate of 50,323 shares of its common stock to two newly hired, non-executive employees.

Compensation Committee approves grants under 2026 Inducement Plan

The Compensation Committee of the company's Board of Directors approved the awards, which carry a grant date of October 15, 2026. They were issued under the company's 2026 Inducement Plan as an inducement material to each employee's entering into employment with the company.

Glendale, Calif. – October 15, 2026 -- Reveleer has appointed Jean-Luc ("JL") Neptune, MD, MBA, as Chief Medical Officer to lead clinical strategy across risk adjustment, quality, and member management programs serving 12 million covered lives.

Neptune will set clinical direction for Reveleer products and shape the company's approach to AI, value-based care, and health care payment reform. He brings more than 20 years of experience putting new technology in front of clinicians at the point of care, first as a physician and later as a digital health founder.

Arlington – October 15, 2026 -- The Bone Health and Osteoporosis Foundation (BHOF) has named Kenneth G. Saag, M.D., M.Sc., North American Editor-in-Chief of Osteoporosis International (OI) for a five-year term starting Dec. 15, 2026.

Ipswich, Mass. – October 15, 2026 -- New England Biolabs (NEB) has secured co-exclusive rights to sell seqWell's TnX Transposase and the right to manufacture the enzyme and include it in NEB kits and products, under a strategic partnership announced alongside the commercial launch of TnX Transposase (Unloaded).

Westlake, Texas – October 15, 2026 -- Virbac has donated more than 29,000 doses of IVERHART MAX Chews to KC Pet Project, the municipal animal shelter for Kansas City, Missouri, to protect its dogs against heartworm disease and intestinal parasites.

Shelter treats 300 heartworm-positive dogs while screening 8,263 intakes

KC Pet Project cares for more than 16,000 pets each year. It took in 8,263 dogs over the past 12 months, and each receives preventive care at intake. The donation supports that standard of care for every dog entering the shelter.

Global – – October 15, 2026 -- Only 17% of health and life sciences leaders report a centralized approach to internal data governance, according to 2026 Voice of Our Clients (VOC) research, even as organizations move generative AI from pilots into production.